NEW YORK, Sept. 14, 2011 /PRNewswire/ -- Napoleone Ferrara, M.D., will receive the Johnson & Johnson Dr. Paul Janssen Award for Biomedical Research, including a $100,000 prize, this week during a series of events that celebrate his central role in the discovery of vascular endothelial growth factor (VEGF), the core signaling molecule of angiogenesis. His research has opened the door to the development of a new class of therapeutics to combat a serious eye disorder and contributed to the development of new oncology therapeutics. The Award aims to extend the legacy of Dr. Paul Janssen, an exceptionally gifted and passionate scientist who revolutionized modern medicine and inspired a new generation of researchers, by honoring the work of an active scientist in academia, industry or a scientific institute who has made a significant contribution to advancing human health.
"Dr. Ferrara's groundbreaking research has made a direct impact on the quality of life of many thousands of people," said Paul Stoffels, M.D., Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. "We are pleased to recognize Dr. Ferrara's important achievements in advancing human well-being and his ongoing commitment to scientific innovation that embody the spirit of Dr. Paul Janssen."
Dr. Ferrara received recognition for this achievement at a reception last night and is also being honored during a scientific symposium today at the New York Academy of Sciences in New York. A formal award ceremony to honor Dr. Ferrara will also take place at the Dr. Paul Janssen Research Center in Beerse, Belgium tomorrow.
The symposium will feature presentations by Dr. Ferrara and other internationally renowned experts who have a seminal role in advancing anti-angiogenic therapies for ocular di
|SOURCE Johnson & Johnson|
Copyright©2010 PR Newswire.
All rights reserved